Keywords :
Fibrosis, Intralesional injections, Laser therapy, OSMF grade II
Citation Information :
Das A, Rana P, Raghunandanan S, Panicker P, Kumar PM. Comparative Evaluation of Low-level Laser Therapy and Intralesional Injection in OSMF Patients: A Quasi-randomized Trial. J Contemp Dent Pract 2024; 25 (8):745-750.
Aim: The aim of the present study was to compare the effectiveness of low-level laser therapy and intralesional injection in oral submucous fibrosis (OSMF) patients.
Materials and methods: The present study comprised of 52 grade II OSMF patients aged between 20 and 60 years. A pretreatment assessment was done for each patients. And 52 patients were divided into two groups (26 patients in each group). Group I received intralesional injections, and group II received low-level laser therapy (LLLT). The intralesional injection group received 0.5 mL 1500 I.U. Hyaluronidase with 2 mL dexamethasone biweekly for a month. The LLLT group underwent sessions of 0.1 watt laser only once for 3 cycles, each lasting 1 minute with 5-minute intervals. Evaluation of overall accessibility, burning sensation and mouth opening was done for both the treatment modalities on 0, 3rd, 7th and 15th day. All data were recorded and statistically analyzed.
Results: On comparison of burning sensation in intralesional Injection group, at baseline, the mean value was 4.00 ± 0.84 and it reduced to 1.19 ± 0.40 while in LLLT group from 4.15 ± 0.96 at baseline, it reduced to 2.65 ± 0.68 at the end of 15 days, respectively. On comparison of mouth opening in intralesional Injection group, at baseline, the mean value was 21.73 ± 1.56 and it increased to 32.53 ± 0.97 while in LLLT group from 22.70 ± 2.17 at baseline, it increased to 24.50 ± 1.31 at the end of 15 days, respectively. There was a statistically significant difference found between the two groups.
Conclusion: The present study concluded that intralesional injections are more effective in treating grade II OSMF compared with LLLT.
Clinical significance: Several different treatment options are available to treat OSMF, including medical approaches, surgical management, and physiotherapy. One of the important therapeutic modalities is intralesional injection therapy with corticosteroids as they reduce inflammation and immunosuppression while hyaluronidase increases tissue permeability.
Mukherjee AL, Biswas SK. Oral submucous fibrosis—a search for Aetiology. Ind J Otol 1972;24(1):11–15. DOI: 10.1007/BF02991934.
Utsunomiya H, Tilakaratne WM, Oshiro K, et al. Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. J Oral Pathol Med. 2005;34(8):498–507. DOI: 10.1111/j.1600-0714.2005.00339.x.
Divyadharsini V, Maheswari TN. Lycopene and vitamin E combination for the management of oral potentially malignant disorders – A systematic review. J Popul Ther Clin Pharmacol 2023;30:187–196. 10.47750/jptcp.2023.30.10.023.
Lins RDAU, Dantas EM, Lucena KCR, et al. Biostimulation effects of low-power laser in the repair process. An Bras Dermatol 2010;85(6):849–855. DOI: 10.1590/s0365-05962010000600011.
Kamath VV. Surgical interventions in oral submucous fibrosis: a systematic analysis of the literature. J Maxillofac Oral Surg 2015;14(3):521–531. DOI: 10.1007/s12663-014-0639-3.
Walsh LJ. The current status of low level laser therapy in dentistry. Part 1. Soft tissue applications. Aust Dent J 1997;42(4):247–254. DOI: 10.1111/j.1834-7819.1997.tb00129.x.
Haider SM, Merchant AT, Fikree FF, et al. Clinical and functional staging of oral submucous fibrosis. Br J Oral Maxillofac Surg 2000;38(1):12–15. DOI: 10.1054/bjom.1999.0062.
Qin X, Ning Y, Zhou L, et al. Oral submucous fibrosis: etiological mechanism, malignant transformation, therapeutic approaches and targets. Int J Mol Sci 2023;24(5):4992. DOI: 10.3390/ijms24054992.
James L, Shetty A, Rishi D, et al. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in Grade III oral submucous fibrosis: aretrospective study. J Int Oral Health 2015;7(8):82–85. PMID: 26464545.
Saalim M, Sansare K, Ali IK, et al. Efficacy of betamethasone, hyaluronidase and its combination on mouth opening, burning sensation and QOL in patients with OSF. J Oral BiolCraniofac Res. 2020;10(4):492–411. DOI: 10.1016/j.jobcr.2020.07.007.
Sathyanarayanan R, Jude NJ, Guna TP, et al. Management of oral submucous fibrosis with intralesional injection of hyaluronidase and dexamethasone: a case report. Journal of Scientific Dentistry. 2021 Feb 4;10(2):41–42. DOI: 10.5005/jp-journals-10083-0924.
Chandra S, Gujjari SK, Sankar AR. Biostimulation with diode lasers: A novel futuristic approach in the treatment of oral submucous fibrosis – A case report. Int J Med Dent Case Rep 2019;6:1–4. DOI: 10.15713/ins.ijmdcr.127.
Sukanya D, Upasana L, Deepak TA, et al. Determination of effectiveness of photobiomodulation in the treatment of oral submucous fibrosis. J Pharm Bioallied Sci. 2022 Jul;14(Suppl 1):S475–478. DOI: 10.4103/jpbs.jpbs_673_21.
Burde NN, Gayathri S. Diode laser in synergy with pharmacological therapy in treatment of OSMF. Journal of Dental Specialities. 10(1):27–30. Available from: https://www.jdsits.in/article-details/16188.
Aparna TY, Pushpanjali M, Aruna P, et al. Evaluation of the efficacy of laser biostimulation and intralesional triamcinolone acetonide in OSMF: A clinical study. J Indian Acad Oral Med Radiol 2023;35:197–201. DOI: 10.4103/jiaomr.jiaomr_70_23.